One of these approaches involves the application of PKC inhibitors, which have exhibited encouraging outcomes in both preclinical studies and clinical trials, implying that targeting the PKC pathway could be a viable cancer therapy method [166]. This evidence concerns the gene PRRT2 and cancer.